AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference
November 15, 2021 19:24 ET
|
AnaptysBio, Inc.
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
November 15, 2021 09:00 ET
|
AnaptysBio, Inc.
Rosnilimab, AnaptysBio’s wholly-owned anti-PD-1 agonist antibody, demonstrated favorable safety and tolerability in single and multiple ascending dose healthy volunteer cohortsRobust pharmacokinetic...
AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates
November 04, 2021 16:05 ET
|
AnaptysBio, Inc.
Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and GEMINI-1 Phase 3 trial initiated subsequent to FDA end-of-Phase 2 meetingTop-line data from ongoing imsidolimab ACORN...
AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard
October 25, 2021 16:37 ET
|
AnaptysBio, Inc.
AnaptysBio to receive $250 million upfront cash payment from Sagard Healthcare Royalty PartnersSagard to receive AnaptysBio’s 8% royalty on annual global net sales of JEMPERLI (dostarlimab-gxly) below...
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis
October 02, 2021 12:00 ET
|
AnaptysBio, Inc.
Imsidolimab demonstrated rapid and sustained efficacy with 6 of 8 (75%) generalized pustular psoriasis (GPP) patients achieving the primary endpoint at week 4 and week 16Early reduction of erythema...
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 16:05 ET
|
AnaptysBio, Inc.
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors
August 17, 2021 16:32 ET
|
AnaptysBio, Inc.
Second FDA Approval of PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GSKJEMPERLI Was Approved For dMMR Endometrial Cancer in the US and Europe in April...
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates
August 09, 2021 16:05 ET
|
AnaptysBio, Inc.
Imsidolimab GPP GEMINI-1 Phase 3 trial anticipated to initiate in Q3 2021 following recent FDA end-of-Phase 2 MeetingImsidolimab GALLOP GPP Phase 2 trial 16-week data to be orally presented at the...
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
May 27, 2021 16:15 ET
|
AnaptysBio, Inc.
SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates
May 04, 2021 16:05 ET
|
AnaptysBio, Inc.
Imsidolimab Phase 3 GPP trial anticipated to commence in mid-2021 following FDA end-of-Phase 2 meeting held during Q2 2021JEMPERLI (dostarlimab), our PD-1 antagonist antibody partnered with...